Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack

Mar 14, 2010 10:00am EDT

XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients

Mar 12, 2010 9:00am EST

XOMA Reports 2009 and Fourth Quarter Financial Results

Mar 11, 2010 4:05pm EST

XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11

Mar 04, 2010 5:02pm EST

XOMA to Webcast Presentations From Two March 2010 Investment Conferences

Feb 25, 2010 8:00am EST

XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients

Feb 09, 2010 7:00am EST

XOMA Announces Presentation at BIO CEO and Investor Conference on February 9

Feb 03, 2010 4:02pm EST

XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants

Feb 02, 2010 8:45am EST

XOMA Reviews Priorities for 2010 and 2009 Accomplishments

Jan 19, 2010 7:30am EST

XOMA Reports Removal of "Going Concern" Qualification

Dec 22, 2009 9:10am EST
RSS
  • Prev
    • 1...
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top